Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Director Dennis A. Ausiello sold 20,000 shares of the company’s stock in a transaction that occurred on Thursday, November 2nd. The stock was sold at an average price of $130.00, for a total transaction of $2,600,000.00. Following the transaction, the director now owns 20,000 shares of the company’s stock, valued at $2,600,000. The transaction was disclosed in a filing with the SEC, which is available through this link.

Alnylam Pharmaceuticals, Inc. (NASDAQ ALNY) traded up $11.27 during trading on Friday, hitting $132.36. 1,486,383 shares of the company were exchanged, compared to its average volume of 1,126,231.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its earnings results on Wednesday, August 9th. The biopharmaceutical company reported ($1.34) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($1.22) by ($0.12). Alnylam Pharmaceuticals had a negative net margin of 743.28% and a negative return on equity of 48.62%. The company had revenue of $15.93 million for the quarter, compared to analyst estimates of $23.86 million. During the same quarter in the previous year, the firm earned ($1.05) EPS. The firm’s revenue was up 82.9% on a year-over-year basis. equities research analysts expect that Alnylam Pharmaceuticals, Inc. will post -5.08 earnings per share for the current year.

COPYRIGHT VIOLATION WARNING: “Alnylam Pharmaceuticals, Inc. (ALNY) Director Dennis A. Ausiello Sells 20,000 Shares” was first published by American Banking News and is the sole property of of American Banking News. If you are accessing this piece on another website, it was illegally copied and reposted in violation of US and international trademark and copyright laws. The original version of this piece can be read at https://www.americanbankingnews.com/2017/11/03/alnylam-pharmaceuticals-inc-alny-director-dennis-a-ausiello-sells-20000-shares.html.

Several institutional investors have recently added to or reduced their stakes in the stock. FMR LLC lifted its position in shares of Alnylam Pharmaceuticals by 6.3% during the 2nd quarter. FMR LLC now owns 13,723,153 shares of the biopharmaceutical company’s stock valued at $1,094,559,000 after acquiring an additional 815,270 shares during the period. Vanguard Group Inc. lifted its position in shares of Alnylam Pharmaceuticals by 13.4% during the 2nd quarter. Vanguard Group Inc. now owns 6,419,508 shares of the biopharmaceutical company’s stock valued at $512,020,000 after acquiring an additional 759,295 shares during the period. BlackRock Inc. lifted its position in shares of Alnylam Pharmaceuticals by 9.3% during the 2nd quarter. BlackRock Inc. now owns 5,188,191 shares of the biopharmaceutical company’s stock valued at $413,811,000 after acquiring an additional 441,957 shares during the period. Baillie Gifford & Co. lifted its position in shares of Alnylam Pharmaceuticals by 2.9% during the 2nd quarter. Baillie Gifford & Co. now owns 3,431,316 shares of the biopharmaceutical company’s stock valued at $273,681,000 after acquiring an additional 96,805 shares during the period. Finally, First Trust Advisors LP lifted its position in shares of Alnylam Pharmaceuticals by 25.3% during the 3rd quarter. First Trust Advisors LP now owns 784,619 shares of the biopharmaceutical company’s stock valued at $92,185,000 after acquiring an additional 158,288 shares during the period. Institutional investors own 94.39% of the company’s stock.

A number of equities analysts recently issued reports on the stock. Cowen and Company reiterated an “outperform” rating and set a $151.00 price objective (up from $117.00) on shares of Alnylam Pharmaceuticals in a research report on Friday. Credit Suisse Group boosted their target price on shares of Alnylam Pharmaceuticals from $123.00 to $151.00 and gave the stock an “outperform” rating in a report on Friday. Needham & Company LLC boosted their target price on shares of Alnylam Pharmaceuticals from $125.00 to $152.00 and gave the stock a “buy” rating in a report on Friday. B. Riley started coverage on shares of Alnylam Pharmaceuticals in a report on Wednesday. They set a “buy” rating and a $240.00 target price on the stock. Finally, Piper Jaffray Companies reissued an “overweight” rating and set a $14.71 target price (down from $188.00) on shares of Alnylam Pharmaceuticals in a report on Thursday. Three equities research analysts have rated the stock with a sell rating, seven have issued a hold rating and sixteen have issued a buy rating to the stock. The company has an average rating of “Buy” and an average target price of $109.66.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).

Insider Buying and Selling by Quarter for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Receive News & Ratings for Alnylam Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.